ONCC Certification Test Results Are Announced

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

PITTSBURGH-The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.

PITTSBURGH—The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.

Of nearly 3,000 nurses who took the Oncology Certified Nurse (OCN) test, 2,503 (85%) passed, including 1,409 who were newly certified and 1,094 who renewed their credential.

More than 300 registered nurses took the Certified Pediatric Oncology Nurse (CPON) examination, and 244 (77%) passed, 150 who were newly certified and 94 who renewed their CPON certification.

Articles in this issue
ODAC Sends Mixed Message on New Gliadel Wafer Indication
ONCC Certification Test Results Are Announced
Rituximab Ups Survival in Aggressive and Indolent NHL
Topotecan Used in Aggressive Front-Line Therapy for SCLC
Depsipeptide Shows Activity in T-Cell Lymphoma
FDG-PET Useful in Newly Diagnosed and Recurrent NSCLC
Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trial
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insert
FDA and VA Plan Joint AIDS Study
Breast Conservation Increases With On-Site Radiation Unit
Washington State Hikes Cigarette Tax
Moffitt’s Diet Guidelines for Immunocompromised Patients
AMA Approves New CPT Code for Serum HER-2 Test
NCI Formalizes Role of Advocates
Better Prognosis for Outer Quadrant Breast Cancers

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese
June 6th 2025
Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Ashling Wahner
June 5th 2025
Article

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.